Dirithromycin

This image is provided by the National Library of Medicine.

WikiDoc Resources for Dirithromycin
Articles
Most recent articles on Dirithromycin Most cited articles on Dirithromycin Review articles on Dirithromycin Articles on Dirithromycin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Dirithromycin Images of Dirithromycin Photos of Dirithromycin Podcasts & MP3s on Dirithromycin Videos on Dirithromycin
Evidence Based Medicine
Cochrane Collaboration on Dirithromycin Bandolier on Dirithromycin TRIP on Dirithromycin
Clinical Trials
Ongoing Trials on Dirithromycin at Clinical Trials.gov Trial results on Dirithromycin Clinical Trials on Dirithromycin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Dirithromycin NICE Guidance on Dirithromycin NHS PRODIGY Guidance FDA on Dirithromycin CDC on Dirithromycin
Books
Books on Dirithromycin
News
Dirithromycin in the news Be alerted to news on Dirithromycin News trends on Dirithromycin
Commentary
Blogs on Dirithromycin
Definitions
Definitions of Dirithromycin
Patient Resources / Community
Patient resources on Dirithromycin Discussion groups on Dirithromycin Patient Handouts on Dirithromycin Directions to Hospitals Treating Dirithromycin Risk calculators and risk factors for Dirithromycin
Healthcare Provider Resources
Symptoms of Dirithromycin Causes & Risk Factors for Dirithromycin Diagnostic studies for Dirithromycin Treatment of Dirithromycin
Continuing Medical Education (CME)
CME Programs on Dirithromycin
International
Dirithromycin en Espanol Dirithromycin en Francais
Business
Dirithromycin in the Marketplace Patents on Dirithromycin
Experimental / Informatics
List of terms related to Dirithromycin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Dirithromycin is a macrolide glycopeptide antibiotic. Dirithromycin (Dynabac) is a more lipid-soluble prodrug derivative of 9S-erythromycyclamine prepared by condensation of the latter with 2-(2-methoxyethoxy)acetaldehyde. The 9N, 11O-oxazine ring thus formed is a hemi-aminal that is unstable under both acidic and alkaline aqueous conditions and undergoes spontaneous hydrolysis to form erythromycyclamine. Erythromycyclamine is a semisynthetic derivative of erythromycin in which the 9-ketogroup of the erythronolide ring has been converted to an amino group. Erythromycyclamine retains the antibacterial properties of erythromycin oral administration. The prodrug, dirithromycin, is provided as enteric coated tablets to protect it from acid catalyzed hydrolysis in the stomach. Orally administered dirithromycin is absorbed rapidly into the plasma, largely from the small intestine. Spontaneous hydrolysis to erythromycyclamine occurs in the plasma. Oral bioavailability is estimated to be about 10%, but food does not affect absorption of the prodrug.

Discontinuation

Dirithromycin is no longer available in the United States. Since the production of dirithromycin is discontinued in the U.S, National Institutes of Health recommend that people taking dirithromycin should consult their physicians to discuss switching to another treatment. However, dirithromycin is still available in many european countries.